The US: To Go, or Not to Go?
Whether or not European biotechs should establish operations in the US may seem like a no brainer: it's the biggest drugs market, with more potential partners, better funding, more promising exits for investors and a more experienced management pool than Europe. But getting there-and getting noticed-isn't easy. And since most executives agree that going to the US half-heartedly isn't worthwhile, Europe's biotechs need to think hard about when and whether they're ready to go. For a minority, setting up in the US may not be the right solution-for now.
You may also be interested in...
Europe's investment environment has forced much of the biotech sector to morph into specialty pharma. The situation isn't likely to change fast. Executives had best adapt, rather than complain.
Biogen Idec's decision to move its international headquarters from Paris to Switzerland reflects the growing size, and changing structure, of its international business. It also increases Switzerland's already strong allure as Europe's friendliest biotech hub.
A late-June listing may help Germany's GPC Biotech AG attract investor interest and it certainly reinforces the firm's increasing Americanization. Yet the performance of lead candidate satraplatin remains the strongest determinant of GPC's valuation and near-term success.